Introduction
============

Gestational trophoblastic disease (GTD) is a group of rare gynecologic tumors comprised of heterogeneous types of abnormal placental development. The disease includes complete and partial hydatidiform moles (HM) and gestational trophoblastic neoplasia (GTN), which encompasses choriocarcinomas (CC), placental site trophoblastic tumors, epithelioid trophoblastic tumors, and invasive moles ([@ref-15]; [@ref-25]). The exact incidence of GTD is difficult to ascertain because of its rarity and geography-associated variation ([@ref-5]), as well as inconsistent definitions and diagnostic criteria, inadequate histological examinations, and differences in how births are classified ([@ref-7]; [@ref-19]). Incidence of GTD has decreased over time in Asia ([@ref-13]; [@ref-18]), whereas some European countries have reported steady or increased rates ([@ref-7]; [@ref-10]; [@ref-16]). Thus, more recent and accurate data are necessary to evaluate actual incidence rates of GTD.

Our present study investigates the longitudinal incidence rates of GTD in South Korea between 2009 and 2015 using population-based demographic and clinical data. We also compare incidence rates and trends with those in Western population-based studies and reports from South Korea before 2005.

Materials and Methods
=====================

Study data participants
-----------------------

Most residents of the Republic of Korea (more than 98%) are covered by the National Health Insurance. The Health Insurance Review and Assessment Service (HIRA) reviews nearly all medical claims between the insurance service and medical institutions. The HIRA annually provides the HIRA-National Inpatient Sample (HIRA-NIS), a collection of clinical data from over one million people. HIRA-NIS data from 2009 to 2015 were used for this study (serial numbers 2009-0066, 2010-0084, 2011-0063, 2012-0058, 2013-0085, 2014-0068, and 2015-0057). For each year, we extracted records of 13% of patients admitted at any one time during the year and 1% of all remaining patients using the weighted sample method ([@ref-12]).

Diagnostic and demographic data collection
------------------------------------------

The Korean Standard Classification of Diseases (7th edition), adapted from the International Statistical Classification of Diseases and Related Health Problems (10th edition) and the HIRA Drug Ingredients Codes and 2016 Health Insurance Medical Care Expenses were used to diagnose GTD. Diagnosis codes for HM (O01.x), invasive HM (D39.2), or malignant neoplasm of placenta (C58.x) denoted GTD, and associated operative procedure codes included those for aspiration biopsies (C8573), simple curettage (C8574), uterine suction curettage (R4481), total hysterectomy (R4482), dilatation, and curettage (R4521), simple hysterectomy with lymphadenectomy (R4143), complex hysterectomy with lymphadenectomy (R4144), simple abdominal hysterectomy (R4145), complex abdominal hysterectomy (R4146), radical hysterectomy with bilateral pelvic lymphadenectomy with para-aortic lymph node biopsy (R4154), radical hysterectomy with bilateral pelvic lymphadenectomy without para-aortic lymph node biopsy (R4155), subtotal hysterectomy (R4130), vaginal hysterectomy (R4202), and vaginal hysterectomy with anterior and posterior repairs (R4203).

Types of pregnancy and/or delivery included ectopic pregnancy (O00.x), other abnormal products of conception (O02.x), spontaneous abortion (O03.x), medical abortion (O04.x), other abortion (O05.x), unspecified abortion (O06.x), normal delivery (O80.x), single delivery by forceps and vacuum extractor (O81.x), single delivery by Cesarean section (O82.x), other assisted single delivery (O83.x), and multiple delivery (O84.x). Antenatal care of normal pregnancy was defined as incidental pregnant state (Z33.x) or supervision of normal pregnancy (Z34.x).

Diagnosis of GTD, ectopic pregnancy, abortion, and antenatal care of normal pregnancy is often not confirmed, so if multiple consecutive diagnostic codes were assigned within 60 days of each other, the last chronological code was used as the final diagnosis. If diagnostic codes were used in intervals greater than 60 days, each code was classified as a distinct diagnosis.

Total number of pregnancies was defined as the sum of GTD cases, ectopic pregnancies, abortions, and deliveries. The incidence rate of GTD was defined as the sum of GTD cases divided by total pregnancies, excluding antenatal care of pregnancy due to overlap with number of deliveries. Low socioeconomic status (SES) was defined as use of a non-general insurance code, such those used for recipients of livelihood programs and homeless individuals.

Statistical analysis
--------------------

All statistical analyses were performed with R version 3.3.2 ([@ref-34]). All tests were two-tailed and defined as statistically significant when the *P*-value was less than 0.05. Weighted analysis was performed to calculate the incidences and mean ages of the population. The Student's *t*-test was used to compare continuous variable means, and Pearson's chi-square or Fisher's exact test was used to compare categorical variables. Odds ratios (OR) of independent variables were determined with logistic regression analysis.

Ethical statement
-----------------

Because this study used data from patients who could not be personally identified, our protocol was not subject to approval by our hospital's institutional review board according to the Korean Bioethics and Safety Act.

Results
=======

The medical records of 370,117 women with at least one pregnancy were extracted from a total of 4,476,495 patients from 2009 to 2015. We identified 372 episodes of GTD among women with an average age of 35.4 ± 0.7 years (31.1 ± 0 years for those without GTD). [Table 1](#table-1){ref-type="table"} presents GTD case frequency and type according to year. The incidence rate of GTD between 2009 and 2015 was 130 ± 10 cases per 100,000 pregnancies, which included HM, invasive HM, and malignant neoplasm of the placenta (110 ± 10, 20 ± 0, and 10 ± 0 cases per 100,000 pregnancies, respectively ([Table 2](#table-2){ref-type="table"})). [Figure 1](#fig-1){ref-type="fig"} shows the incidence rates of GTD according to study year, while [Fig. 2](#fig-2){ref-type="fig"} illustrates GTD incidence with respect to patient age. The lowest incidence of GTD occurred in patients in their late 20 s and early 30 s and the highest in patients in their late 40 s and beyond. HM accounted for 80.3% of all GTD cases, followed by invasive HM (13.1%), and malignant neoplasm of the placenta (6.6%). According to weighted logistic analysis, age significantly correlated with incidence of GTD (OR: 2.46; 95% CI \[1.79--3.37\]; *P* \< 0.001), but sample year (OR: 0.94; 95% CI \[0.8--1.02\]; *P* = 0.108) and SES did not (OR: 1.94; 95% CI \[1.0--3.79\]; *P* = 0.051) ([Table 3](#table-3){ref-type="table"}).
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###### Annual gestational trophoblastic disease cases in South Korea from 2009 to 2015.

![](peerj-07-6490-g003)

                                                       2009         2010         2011         2012         2013         2014          2015         *P*
  ---------------------------------------------------- ------------ ------------ ------------ ------------ ------------ ------------- ------------ ----------------------------------------
  Age                                                  32.6 ± 8.9   37.0 ± 9.1   35.6 ± 9.1   34.9 ± 9.8   38.0 ± 9.5   35.1 ± 10.7   34.9 ± 8.3   0.292
  Hydatidiform mole[^+^](#table-1fn2){ref-type="fn"}   51 (82.3%)   53 (77.9%)   38 (71.7%)   48 (78.7%)   37 (67.3%)   33 (82.5%)    25 (75.8%)   0.482
  Complete hydatidiform mole                           4 (6.5%)     6 (8.8%)     5 (9.4%)     11 (18.0%)   6 (10.9%)    4 (10.0%)     2 (6.1%)     0.526[^a^](#table-1fn3){ref-type="fn"}
  Partial hydatidiform mole                            7 (11.3%)    8 (11.8%)    10 (18.9%)   5 (8.2%)     3 (5.5%)     3 (7.5%)      1 (3.0%)     0.255[^a^](#table-1fn3){ref-type="fn"}
  Invasive hydatidiform mole                           9 (14.5%)    5 (7.4%)     11 (20.8%)   5 (8.2%)     10 (18.2%)   4 (10.0%)     6 (18.2%)    0.211[^a^](#table-1fn3){ref-type="fn"}
  Malignant neoplasm of the placenta                   2 (3.2%)     10 (14.7%)   4 (7.5%)     8 (13.1%)    8 (14.5%)    3 (7.5%)      2 (6.1%)     0.226[^a^](#table-1fn3){ref-type="fn"}

**Notes:**

*N* represents the number of cases.

Hydatidiform mole includes complete, partial, and unspecified hydatidiform mole.

Fisher's exact test was used for data analysis.
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###### Estimated gestational trophoblastic disease rates per 100,000 total pregnancies from 2009 to 2015 in the Republic of Korea.

![](peerj-07-6490-g004)

                                                                       Value ± standard error
  -------------------------------------------------------------------- ------------------------
  Gestational trophoblastic diseases[\*](#table-2fn1){ref-type="fn"}   130 ± 10
  Hydatidiform mole[^+^](#table-2fn2){ref-type="fn"}                   110 ± 10
  Complete hydatidiform mole                                           10 ± 0
  Partial hydatidiform mole                                            10 ± 0
  Invasive hydatidiform mole                                           20 ± 0
  Malignant neoplasm of the placenta                                   10 ± 0

**Notes:**

When a patient had more than two gestational trophoblastic conditions, that case was calculated as one episode.

Hydatidiform mole includes complete, partial, and unspecified hydatidiform mole.

![Trending incidence rates of gestational trophoblastic disease, hydatidiform mole, invasive hydatidiform mole, and malignant neoplasm of the placenta in South Korea from 2009 to 2015.](peerj-07-6490-g001){#fig-1}

![Stratified 5-year patient age ranges of GTD, hydatidiform mole, invasive hydatidiform mole, and malignant neoplasm of the placenta per 100,000 pregnancies in South Korea.](peerj-07-6490-g002){#fig-2}

10.7717/peerj.6490/table-3

###### Multivariate logistic regression analysis of risk factors for gestational trophoblastic disease.

![](peerj-07-6490-g005)

                             Gestational trophoblastic diseases   Hydatidiform mole   Invasive hydatidiform mole   Malignant neoplasm of placenta                                                     
  -------------------------- ------------------------------------ ------------------- ---------------------------- -------------------------------- ------------------- --------- ------------------- ---------
  5-year patient age range   2.46 (1.79--3.37)                    \<0.001             2.14 (1.45--3.16)            \<0.001                          3.51 (2.33--5.3)    \<0.001   3.22 (2.13--4.88)   \<0.001
  Sample year                0.9 (0.8--1.02)                      0.108               0.87 (0.76--1.01)            0.063                            1.04 (0.77--1.4)    0.8       0.93 (0.8--1.08)    0.322
  SES                        1.94 (1--3.79)                       0.051               1.75 (0.81--3.8)             0.156                            2.45 (0.66--9.15)   0.182     1.71 (0.22--13.3)   0.608

**Note:**

OR, odds ratio.

SES, socioeconomic status.

Discussion
==========

Gestational trophoblastic disease consists of various malignancies derived from abnormal trophoblastic proliferation, including complete and partial HM, exaggerated placental site, placental site nodule, invasive HM, CC, placental site trophoblastic tumor, and epithelioid trophoblastic tumor, the latter three of which are considered GTNs ([@ref-25]). Histologic examination of uterine evacuation specimens is essential for HM diagnosis. Distinguishing among complete mole, partial mole, and hydropic abortus at earlier gestational ages is difficult and sometimes impossible using light microscopy alone. When pathologic findings are also not definitive, accurate diagnosis is performed through ancillary methods, including immunostaining and DNA genotyping ([@ref-22]). In our study, diagnosis of HM was made histologically, with unspecified HM in 73.7% of cases, partial HM in 13.3% of cases, and complete HM in 13% of cases. A total of 73.7% of HM cases were coded as unspecified HM with no subcategory code as complete or partial HM. In South Korea, pathologists often do not consider differential diagnostic reports to identify partial and complete HM because this reporting is not mandatory. Unlike other malignant tumors, the diagnosis of GTN is made primarily based on combined clinical presentation and pathologic criteria. Based on GTN subtype, histological confirmation may be problematic in the absence of definitive histologic specimens and should be correlated with serum β-human chorionic gonadotropin levels and radiological findings. GTN is unique in that treatment and surveillance must sometimes be based more on clinical, rather than histological, characteristics of the disease ([@ref-15]). A centralized pathology review and registration system should be established to ensure more accurate pathologic data and concise diagnostic coding.

The reported incidence of HM varies considerably across different geographic regions ([@ref-1]; [@ref-19]) due to imprecise definitions and diagnoses of GTD, inadequacy of histological examinations, and inconsistent use of denominators used (e.g., the number of deliveries, live births, pregnancies, etc.) ([@ref-7]; [@ref-19]). Population-based data, rather than earlier hospital-based data, better reflect trends in GTD incidence rates. Determining the total number of pregnancies is difficult, so the number of deliveries or live births are typically used as surrogate parameters, although the total number of pregnancies is the most ideal denominator ([@ref-1]; [@ref-10]) and should include all live births, stillbirths, abortions, ectopic pregnancies, and clinically unrecognized pregnancies. Use of these specific pregnancy statuses contributes to more accurate estimates of GTD incidence rates across geographic regions ([@ref-7]). In South Korea, pregnancy-related diseases are covered by National Health Insurance, so pregnancy is confirmed early, and clinically unrecognized pregnancies are rare. Medical institutions are required to record diagnostic codes and issue a medical certificate for pregnancy-related expenses and social benefits for these women. Therefore, HIRA-NIS data include all diagnostic and procedure codes that may occur during pregnancy, which can help determine the exact incidence rate of GTD in South Korea.

In recent population-based studies, the incidence rate of HM was 1.19 case per 1,000 deliveries in the United States, 1.2 case per 1,000 deliveries in Sweden, and 1.67 case per 1,000 deliveries in the Netherlands ([@ref-7]; [@ref-16]; [@ref-23]; [@ref-28]), whereas studies in Asian countries reported a wide range of HM incidence rates. For example, incidence of HM in South Korea ranged from 1.9 to 2.1 cases per 1,000 deliveries ([@ref-13], [@ref-14]; [@ref-17]), and incidence of HM in China ranged from 0.81 to 2.5 cases per 1,000 pregnancies ([@ref-26]; [@ref-27]). The incidence of HM in Japan ranged from 1.5 to 3.05 cases per 1,000 pregnancies ([@ref-18]; [@ref-30]) Indonesia has one of the highest GTD incidence rates globally with over 10 cases per 1,000 pregnancies ([@ref-3]). Studies in East Asia have suggested incidence rates of 1--3 per 1,000 pregnancies ([@ref-2]), although recent data indicate rates lower than or similar those in North America and Europe ([@ref-1]; [@ref-6]; [@ref-17]; [@ref-28]; [@ref-29]). Longitudinal incidence rates of GTD show a decreasing trend in Asia ([@ref-18]; [@ref-27]), while some European countries have experienced increasing rates ([@ref-10]; [@ref-16]). However, direct comparisons of GTD incidence are difficult to make due to diverse populations and different denominators used in these reports. Age-standardized incidence rates of GTD obtained from cancer registry databases are a valuable means of comparing incidence rates in different areas of the world ([@ref-1]; [@ref-28]), so further investigations using such age-standardized data could enhance comparative studies of GTD occurrence.

Incidence rates of HM in South Korea have gradually decreased in reported stratified 5-year increments (cases per 1,000 births): 40.3 in 1971--1975; 16.7 in 1976--1980; 5.4 in 1981--1985; 3.5 in 1986--1990; 2.3 in 1991--1995, 2.1 in 1996--2000, and 1.9 in 2001--2005 ([@ref-11], [@ref-13], [@ref-14]; [@ref-17]). In the present study, we reported an incidence rate of 1.1 cases per 1,000 pregnancies in 2009--2015. Economic development, socio-medical advances, and the national medical insurance program are acknowledged as likely contributors to decreased GTD incidence in South Korea ([@ref-14]; [@ref-25]). GTD incidence rate is reported in 160 cases in 2009, 140 cases in 2010, 110 cases in 2011, 170 cases in 2012, 90 cases in 2013, 90 cases in 2014, and 120 cases per 100,000 pregnancies in 2015. The highest GTD incidence was noted in 2012. However, there was no statistical significant difference in the time trend increase. The annual incidence rates of GTD appear to be stable from 2009 to 2015. In South Korea, a relatively single ethnic nation, the birth rate of women from Southeast Asia due to immigration has been 5% since the early 21st century; the influence of this demographic change on GTD occurrence should be analyzed in future studies.

Maternal age, reproductive and obstetric history, genetic factors, familial clustering, parental blood groups, viral infection, ethnic differences, and environmental and lifestyle factors have been considered as potential etiologic risk factors for development of HM ([@ref-8]; [@ref-21]). Extremes of maternal age and a patient's medical history of GTD are established risk factors for GTD ([@ref-1]). Advanced or adolescent maternal age has consistently correlated with higher rates of complete HM, which has been observed in many countries, including those in Asia, Europe, and North America ([@ref-9]). Compared to women aged 20--35 years, the relative risk of HM is 1.1--10.0 for women under 20 years old, 3.0--11.0 for women older than 40 years, and 107.0--841.0 for women older than 45 years ([@ref-1]; [@ref-20]; [@ref-24]). Our-age specific incidence rate graph ([Fig. 2](#fig-2){ref-type="fig"}) shows a J-shaped curve similar to those reported other prior studies. Prior HM predisposes individuals to another molar pregnancy, although subsequent reproductive outcomes in patients with GTD are similar to those in the general population. However, the risk of repeat molar pregnancy is approximately 1--1.7% ([@ref-4]; [@ref-31]).

Some evidence has illustrated correlation of SES with incidence of HM, but information regarding the impact of SES is inconclusive yet inextricably linked to other potential risk factors, including nutritional and environmental parameters ([@ref-1]) In Korea, Taiwan, and Japan, the incidence rate of GTD decreases as the gross domestic product increases ([@ref-13]; [@ref-32]), but low patient SES did not significantly correlate to GTD incidence rate in this study. The exact relationships between these factors is poorly understood; thus, investigations of other possible GTD etiological risk factors based on case-control studies in different geographic settings are warranted.

Our study has several limitations. First, the HIRA-NIS data used in our study consisted of 1-year sample data that did not include parity information or individual reproductive history, so risk factors other than patient age and SES were not evaluated. Second, data used in this study were based on diagnostic codes without corroborating pathologic findings, so the accuracy of histology-based diagnoses cannot be completely verified. However, HIRA-NIS data are extremely consistent with respect to other gynecology malignancies ([@ref-33]), as National Health Insurance reimburses medical institution only if the diagnosis is confirmed histologically, ensuring few cases of misdiagnosis. Third, Southeast Asian women with relatively high incidence of GTD have accounted for 5% of births in South Korea since the early 21st century, but we could not analyze the impact of these demographic changes on GTD incidence. Despite these limitations, our study yielded longitudinal population-based incidence rates of GTD, including HM using total pregnancies as a comprehensive denominator to include live births, stillbirths, spontaneous abortions, and ectopic pregnancies.

Conclusions
===========

We determined the incidence rates of GTD and HM as 1.3 and 1.1 cases per 1,000 pregnancies, respectively. The use of all pregnancy occurrences, not just live births, provide accurate information to calculate GTD incidence. Maternal age, but not SES, significantly correlated to GTD incidence, similar to what has been reported in Western populations. Trends of GTD incidence in South Korea have decreased overall compared with studies before 2005, and the annual incidence rates of GTD appear to have stabilized from 2009 to 2015.
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